Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
$BTC: Anthony Pompliano Says ‘In Our Darkest Moment, Bitcoin Steps to the Forefront’
-
World Market Trends
-
Bitcoin ($BTC) Price to Rise to $30,000 in Second Half of 2023, VanEck Says
-
How Far Away Is The $50,000 Price From the Bitcoin Market? Here’s What to Watch Out For
-
Is Ether ($ETH) a Better Long-Term Bet Than Bitcoin ($BTC)?